- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00834860
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection. The efficacy and safety of pegylated interferon-alpha plus ribavirin combination therapy and its impact on the outcome in chronic hepatitis C patients concomitant with hepatocellular carcinoma deserve to be elucidated.
The purposes of this study are:
- To evaluate the efficacy and safety of pegylated interferon-alpha 2a plus ribavirin combination therapy in chronic hepatitis C patients concomitant with hepatocellular carcinoma.
- To investigate the role of baseline and on-treatment factors on the response to pegylated interferon-alpha 2a plus ribavirin combination therapy in chronic hepatitis C patients concomitant with hepatocellular carcinoma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Kaohsiung, Taiwan, 807
- Kaohsiung Medical University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male and female patients >18 years of age
- Histopathological diagnosis of hepatocellular carcinoma >3 months before entry (Arm A)
- Received curative therapies, including surgery, ablation therapy or liver transplantation >3 months before entry (ArmA)
- No evidence of hepatocellular carcinoma by imaging or histopathological studies at entry
- Patients have never been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin
- Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test
- Detectable serum HCV-RNA
- Liver biopsy findings consistent with the diagnosis of chronic hepatitis C infection with or without compensated cirrhosis (Exception: hemophiliacs in whom biopsy is medically contra-indicated do not require biopsy.)
- Compensated liver disease (Child-Pugh Grade A clinical classification)
- Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
- All fertile males and females receiving ribavirin must be using two forms of effective contraception during treatment and during the 6 months after treatment end
Exclusion Criteria:
- Women with ongoing pregnancy or breast feeding
- Present therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) within 6 months prior to the first dose of study drug
- Any investigational drug 6 weeks prior to the first dose of study drug
- Co-infection with active hepatitis A, hepatitis B and/or human immunodeficiency virus (HIV)
- History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
- Clinical evidence of hepatocellular carcinoma
- History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening
- Serum creatinine level >1.5 times the upper limit of normal at screening
- History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease
- History of a severe seizure disorder or current anticonvulsant use
- History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
- Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)
- Evidence of drug abuse (including excessive alcohol consumption>40 g/day) within one year of study entry
- Inability or unwillingness to provide informed consent or abide by the requirements of the study
- Male partners of women who are pregnant
- Hgb <11 g/dL in women or <12 g/dL in men at screening
- Any patient with major thalassemia
- Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (as may be seen with ribavirin therapy) would not be well-tolerated
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: CHC, HCC
100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
|
They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
Andere Namen:
|
Aktiver Komparator: CHC, LC
100 naïve CHC patients without malignancy
|
They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.
Zeitfenster: 1.5 years
|
1.5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.
Zeitfenster: 1.5 years
|
1.5 years
|
Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.
Zeitfenster: 1.5 years
|
1.5 years
|
Safety: adverse event rate and profile.
Zeitfenster: 1.5 years
|
1.5 years
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Wan-Long Chuang, MD, Kaohsiung Medical University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52. doi: 10.1056/NEJM200107053450107. No abstract available.
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485-92. doi: 10.1056/NEJM199811193392101.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047.
- Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, Hsieh MY, Wang LY, You SL, Chen CJ. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer. 1992 Apr 15;69(8):2052-4. doi: 10.1002/1097-0142(19920415)69:83.0.co;2-n.
- Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology. 2006;49(1-2):99-106. doi: 10.1159/000087271.
- Yu ML, Dai CY, Chen SC, Lee LP, Huang JF, Lin ZY, Hsieh MY, Wang LY, Chuang WL, Chang WY. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res. 2004 Jul;63(1):25-32. doi: 10.1016/j.antiviral.2004.01.002.
- Chuang WL, Dai CY, Chen SC, Lee LP, Lin ZY, Hsieh MY, Wang LY, Yu ML, Chang WY. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver Int. 2004 Dec;24(6):595-602. doi: 10.1111/j.1478-3231.2004.0954.x.
- Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11(8):985-94.
- Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM, Chuang WL, Liaw YF. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther. 2007 May 1;25(9):1029-37. doi: 10.1111/j.1365-2036.2007.03297.x.
- Huang JF, Yeh ML, Yu ML, Dai CY, Huang CF, Huang CI, Tsai PC, Lin PC, Chen YL, Chang WT, Hou NJ, Lin ZY, Chen SC, Chuang WL. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol. 2015 Dec;30(12):1768-74. doi: 10.1111/jgh.13012.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Adenokarzinom
- Neubildungen, Drüsen und Epithelien
- Neoplasmen des Verdauungssystems
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Lebertumoren
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Karzinom
- Hepatitis
- Karzinom, hepatozellulär
- Hepatitis A
- Hepatitis C
- Hepatitis, chronisch
- Hepatitis C, chronisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten
- Ribavirin
- Peginterferon alfa-2a
Andere Studien-ID-Nummern
- KMUH-IRB-960043
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatozelluläres Karzinom
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences CorporationUnbekanntInvasiver Brustkrebs | Duktales Carcinoma in situ der BrustKanada
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Abgeschlossen
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)BeendetBrustkrebsVereinigte Staaten
-
University of AarhusUnbekanntCarcinoma in situ des GebärmutterhalsesDänemark
-
University of Southern CaliforniaBeendetBrustkrebsVereinigte Staaten
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...Aktiv, nicht rekrutierendDuktales Carcinoma in situ der BrustVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossen
-
Brookdale University Hospital Medical CenterUnbekanntCarcinoma in situ des Gebärmutterhalses | Zervikale intraepitheliale Neoplasien | Hochgradige zervikale intraepitheliale NeoplasieVereinigte Staaten
-
Thomas Jefferson UniversityRekrutierungBrustkrebs | Invasiver Brustkrebs | Carcinoma in situ der BrustVereinigte Staaten
-
Danish Breast Cancer Cooperative GroupDanish Cancer SocietyAktiv, nicht rekrutierendBrustkrebs | Carcinoma in situ der BrustDänemark
Klinische Studien zur peginterferon alpha-2a and ribavirin
-
Casa Sollievo della Sofferenza IRCCSUniversity of Palermo; University of Florence; Campus Bio-Medico University; IRCCS... und andere MitarbeiterAbgeschlossen
-
Kaohsiung Medical University Chung-Ho Memorial...Abgeschlossen
-
Miguel SantínAbgeschlossenChronische Hepatitis CSpanien
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción...Abgeschlossen
-
University of NebraskaZurückgezogenChronische Hepatitis CVereinigte Staaten
-
Janssen R&D IrelandAbgeschlossenHepatitis CVereinigte Staaten, Australien, Ukraine, Vereinigtes Königreich, Deutschland, Spanien, Mexiko, Kanada, Neuseeland, Russische Föderation, Puerto Rico, Rumänien
-
Janssen R&D IrelandAbgeschlossenHepatitis CVereinigte Staaten, Australien, Frankreich, Polen, Vereinigtes Königreich, Belgien, Deutschland, Spanien, Kanada, Neuseeland, Russische Föderation, Puerto Rico, Österreich
-
Kaohsiung Medical University Chung-Ho Memorial...Abgeschlossen
-
Baqiyatallah Medical Sciences UniversityShahid Beheshti University of Medical Sciences; Guilan University of Medical... und andere MitarbeiterAbgeschlossenHämophilie | Hepatitis CIran, Islamische Republik
-
Pusan National University Yangsan HospitalPusan National University Hospital; Inje University; Severance Hospital; Soon Chun... und andere MitarbeiterUnbekanntChronische Hepatitis CKorea, Republik von